Health Economics›Colorectal cancer›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Colorectal cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Irinotecan and Cetuximab Variant #03	RAS	R 52 752	14d	2.0 mo	5.9 mo	5	R 263 760 PFS proxy	4
FOLFIRI and Panitumumab Variant #01	RAS	R 28 081	14d	6.7 mo	—	15	R 421 208 PFS proxy	1
FOLFIRI Variant #05	RAS	R 2 826	14d	5.0 mo	12.1 mo	11	R 31 090 PFS proxy	8
Irinotecan monotherapy N/A - secondary systemic drug	RAS	R 47	42d	—	10.9 mo	—	—	4

4 of 4 regimens shown